Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) went up by 6.84% from its latest closing price compared to the recent 1-year high of $1.51. The company’s stock price has collected 2.48% of gains in the last five trading sessions. Press Release reported on 09/09/20 that Thinking about buying stock in iBio Inc, Virgin Galactic, Sorrento Therapeutics, Adamis Pharmaceuticals, or Plug Power?
Is It Worth Investing in Adamis Pharmaceuticals Corporation (NASDAQ :ADMP) Right Now?
Plus, the 36-month beta value for ADMP is at 2.06. Opinions of the stock are interesting as 1 analysts out of 3 who provided ratings for Adamis Pharmaceuticals Corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $1.25, which is $0.47 above the current price. ADMP currently public float of 72.70M and currently shorts hold a 6.33% ratio of that float. Today, the average trading volume of ADMP was 6.24M shares.
ADMP’s Market Performance
ADMP stocks went up by 2.48% for the week, with a monthly drop of -23.14% and a quarterly performance of 23.46%, while its annual performance rate touched -7.76%. The volatility ratio for the week stands at 9.55% while the volatility levels for the past 30 days are set at 13.06% for Adamis Pharmaceuticals Corporation. The simple moving average for the period of the last 20 days is 2.22% for ADMP stocks with a simple moving average of 23.83% for the last 200 days.
Analysts’ Opinion of ADMP
Many brokerage firms have already submitted their reports for ADMP stocks, with Maxim Group repeating the rating for ADMP by listing it as a “Buy.” The predicted price for ADMP in the upcoming period, according to Maxim Group is $1.50 based on the research report published on May 13th of the current year 2020.
Dawson James, on the other hand, stated in their research note that they expect to see ADMP reach a price target of $1.50. The rating they have provided for ADMP stocks is “Neutral” according to the report published on February 27th, 2020.
Raymond James gave a rating of “ Mkt Perform” to ADMP, setting the target price at $1.50 in the report published on November 26th of the previous year.
ADMP Trading at -10.21% from the 50-Day Moving Average
After a stumble in the market that brought ADMP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.08% of loss for the given period.
Volatility was left at 13.06%, however, over the last 30 days, the volatility rate increased by 9.55%, as shares sank -17.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +45.19% upper at present.
During the last 5 trading sessions, ADMP rose by +2.48%, which changed the moving average for the period of 200-days by +35.17% in comparison to the 20-day moving average, which settled at $0.7587. In addition, Adamis Pharmaceuticals Corporation saw 11.94% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ADMP starting from Marguglio David J., who sold 8,749 shares at the price of $0.87 back on Aug 18. After this action, Marguglio David J. now owns 328,539 shares of Adamis Pharmaceuticals Corporation, valued at $7,648 using the latest closing price.
Hopkins Robert O, the Chief Financial Officer of Adamis Pharmaceuticals Corporation, sold 7,418 shares at $0.87 during a trade that took place back on Aug 18, which means that Hopkins Robert O is holding 294,781 shares at $6,484 based on the most recent closing price.
Stock Fundamentals for ADMP
Current profitability levels for the company are sitting at:
- -135.67 for the present operating margin
- +17.80 for the gross margin
The net margin for Adamis Pharmaceuticals Corporation stands at -132.53. The total capital return value is set at -67.13, while invested capital returns managed to touch -69.60. Equity return is now at value -103.20, with -73.70 for asset returns.
Based on Adamis Pharmaceuticals Corporation (ADMP), the company’s capital structure generated 11.32 points at debt to equity in total, while total debt to capital is 10.17. Total debt to assets is 8.28, with long-term debt to equity ratio resting at -243.41. Finally, the long-term debt to capital ratio is 4.11.
When we switch over and look at the enterprise to sales, we see a ratio of 1.47, with the company’s debt to enterprise value settled at 0.13. The receivables turnover for the company is 14.58 and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.34.